The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The role of bevacizumab in combination with pegylated liposomal doxorubicin in patients with platinum-resistant recurrent or refractory ovarian cancers.
H. Kouta
No relevant relationships to disclose
K. Kudoh
No relevant relationships to disclose
M. Takano
No relevant relationships to disclose
R. Kikuchi
No relevant relationships to disclose
T. Kita
No relevant relationships to disclose
T. Goto
No relevant relationships to disclose
K. Furuya
No relevant relationships to disclose
Y. Kikuchi
No relevant relationships to disclose